These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 10366471)

  • 21. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
    Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
    J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activity of chemotherapy in mucinous epithelial ovarian cancer: a retrospective study.
    Pisano C; Greggi S; Tambaro R; Losito S; Iodice F; Di Maio M; Ferrari E; Falanga M; Formato R; Iaffaioli VR; Pignata S
    Anticancer Res; 2005; 25(5):3501-5. PubMed ID: 16101169
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
    Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
    Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paclitaxel, topotecan, and carboplatin in metastatic endometrial cancinoma: a Hellenic Co-operative Oncology Group (HeCOG) study.
    Papadimitriou CA; Fountzilas G; Bafaloukos D; Bozas G; Kalofonos H; Pectasides D; Aravantinos G; Bamias A; Dimopoulos MA;
    Gynecol Oncol; 2008 Oct; 111(1):27-34. PubMed ID: 18644619
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Weekly paclitaxel and carboplatin against advanced transitional cell cancer after failure of a platinum-based regimen.
    Kouno T; Ando M; Yonemori K; Matsumoto K; Shimizu C; Katsumata N; Komiyama M; Okajima E; Matsuoka N; Fujimoto H; Fujiwara Y
    Eur Urol; 2007 Oct; 52(4):1115-22. PubMed ID: 17433855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
    Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
    Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer.
    Gronlund B; Høgdall C; Hansen HH; Engelholm SA
    Gynecol Oncol; 2001 Oct; 83(1):128-34. PubMed ID: 11585424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
    Chang HM; Kim TW; Ryu BY; Choi SJ; Park YH; Lee JS; Kim WK; Kang YK
    Jpn J Clin Oncol; 2005 May; 35(5):251-5. PubMed ID: 15886269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical efficacy analysis of chemotherapy to lymph node metastasis in epithelial ovarian cancer].
    Wu LY; Zhang R; Huang MN; Li N; Wang GX; Liu LY
    Ai Zheng; 2003 Apr; 22(4):424-7. PubMed ID: 12704005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The "Leuven" dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer.
    Cadron I; Leunen K; Amant F; Van Gorp T; Neven P; Vergote I
    Gynecol Oncol; 2007 Aug; 106(2):354-61. PubMed ID: 17499348
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer.
    Duska LR; Berkowitz R; Matulonis U; Muto M; Goodman A; McIntyre JF; Klein A; Atkinson T; Seiden MV; Campos S
    Gynecol Oncol; 2005 Jan; 96(1):198-203. PubMed ID: 15589601
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of 3-h infusion of paclitaxel in patients with adenocarcinoma of endometrium: Japanese Multicenter Study Group.
    Hirai Y; Hasumi K; Onose R; Kuramoto H; Kuzuya K; Hatae M; Ochiai K; Nozawa S; Noda K
    Gynecol Oncol; 2004 Aug; 94(2):471-6. PubMed ID: 15297190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model.
    Mountzios G; Bamias A; Voulgaris Z; Rodolakis A; Vlahos G; Gourgoulis G; Papaiakovou EE; Giannopoulos A
    Gynecol Oncol; 2008 Jan; 108(1):130-5. PubMed ID: 17988722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Taxol is active in platinum-resistant endometrial adenocarcinoma.
    Woo HL; Swenerton KD; Hoskins PJ
    Am J Clin Oncol; 1996 Jun; 19(3):290-1. PubMed ID: 8638543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activity of weekly paclitaxel in patients with advanced endometrial cancer previously treated with both a platinum agent and paclitaxel.
    Markman M; Fowler J
    Gynecol Oncol; 2004 Jan; 92(1):180-2. PubMed ID: 14751155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful treatment of two patients with recurrent endometrial cancer by weekly paclitaxel.
    Ota S; Sugiyama T; Ushijima K; Komai K; Fujiyoshi K; Hirai N; Nishida T; Kamura T
    Cancer Lett; 2000 Nov; 160(1):9-12. PubMed ID: 11098078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Taxol (paclitaxel) was approved by FDA for the treatment of patients with recurrent ovarian cancer.
    Menzin AW; King SA; Aikins JK; Mikuta JJ; Rubin SC
    Gynecol Oncol; 1994 Jul; 54(1):103. PubMed ID: 7912683
    [No Abstract]   [Full Text] [Related]  

  • 40. Exposure to select PFAS and PFAS mixtures alters response to platinum-based chemotherapy in endometrial cancer cell lines.
    Rickard BP; Overchuk M; Tulino J; Tan X; Ligler FS; Bae-Jump VL; Fenton SE; Rizvi I
    Environ Health; 2023 Dec; 22(1):87. PubMed ID: 38098045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.